News
Lupin launches ophthalmic solution in US
IMT News Desk
8 months ago
Lupin launches ophthalmic solution in US
IMT News Desk
8 months ago
The solution is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery
Lupin announced the launch of Bromfenac Ophthalmic Solution, 0.07 per cent, after having received approval from the United States Food and Drug Administration (US FDA). Lupin is the exclusive first-to-file for this product and is eligible for 180-day exclusivity.
Bromfenac Ophthalmic Solution, 0.07 per cent is the generic equivalent of Prolensa Ophthalmic Solution, 0.07 per cent, of Bausch & Lomb. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Bromfenac Ophthalmic Solution (RLD Prolensa) had estimated annual sales of $182 million in the US.
Recommended
Millennium Babycares raises Rs 1220 M from Bharat Value Fund
October 14, 2024
